FDA Drug Information Update for Valsartan-containing Products

PUBLISHED: Jul 25, 2018
Relevant to: Ambulatory Care, Critical Access Hospitals, Home Health, Hospice, Hospitals, Long Term Care, Medical Office, Pharmacy

The U.S. Food and Drug Administration (FDA) released an update for healthcare professionals and consumers on the agency’s progress in responding to the ongoing recalls of valsartan, which is used to treat high blood pressure and heart failure, due to the presence of NDMA. The agency has posted a list of valsartan-containing products not impacted by this recall.

The FDA continues to evaluate valsartan-containing products and will update the list of products included in the recall and the list of products not included in the recall as more information becomes available. Health care professionals and patients should check this site frequently for any updates.

Manufacturers of these products often produce multiple dosage strengths, however not all of them are being recalled. FDA recommends health care professionals and patients carefully check these lists.

Consumers and health care professionals should continue to report any adverse reactions with valsartan-containing products, to the FDA’s MedWatch program to help the agency better understand the scope of the problem.

Want to read the full alert and receive alert emails?

Browse Additional Alerts